Press Releases

Vince and Associates Clinical Research Partners with Private Equity Firm Celerity Partners

recapitalized by
November 2007

Vince and Associates Clinical Research (VNA), a leading independent provider of clinical trial services to the global pharmaceutical and biotechnology industry, announced today it has partnered with private equity investor Celerity Partners (Celerity). This partnership will enable Vince and Associates to strategically expand its leading market presence throughout the Midwest. VNA’s senior management will continue to hold a significant equity interest and will remain actively involved with the company.

“We are very excited to be partnering with such a well respected and knowledgeable firm in the clinical research industry,” said Dr. Brad Vince, Founder, Chief Executive Officer and President of VNA, and a member of the company’s Board of Directors. “This strategic alliance will allow our organization to better serve our pharmaceutical clients by offering additional Midwestern clinical research locations in which to conduct clinical trials,” Vince said.

Since its formation in 2001, VNA has grown to become one of the leading clinical trial services companies in the U.S. specializing in central nervous system research (one of the most rapidly growing segments of biopharmaceutical research) with renowned therapeutic expertise in Sleep Disorders research and other therapeutic specialties. With vast experience in conducting both overnight and outpatient studies, the Company is typically among the fastest and highest enrolling sites in the clinical studies in which it participates.

“VNA has established an exceptional model for recruiting and retaining clinical research participants within a framework of impressive quality controls for clinical trials in large and growing therapeutic areas. The market for specialized clinical development and consulting services to the biopharmaceutical industry continues to expand. VNA is a very strong competitor, offering pharmaceutical and biotechnology companies a fast, cost-effective approach to gaining regulatory approval for promising new compounds. We are delighted to be a partner in VNA’s bright future,” stated Allen Chi, Principal of Celerity.

The transaction with Celerity Partners represents VNA’s first institutional financing. In conjunction with this financing, Allen Chi of Celerity has joined VNA’s Board of Directors.

Edgemont Capital Partners, a leading healthcare investment banking firm to life sciences and pharmaceutical services companies, acted as exclusive financial advisor to VNA in this transaction.

www.edgemontcapital.com

CONTACT:

At Edgemont Capital Partners

David K. Blume, Managing Director
Phone: 212-867-8935 Fax: 212-214-0911

Jeff B. Swearingen, Principal
Phone: 212-867-8935 Fax: 212-937-3816